Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 4/20 | 0.46 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 13/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | YES1 | P07947 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31264106 | 0.92 | SLC40A1 (0.39) | SLC40A1EIF2AK3BRAFPLK4EPHB6 | |
| SCHEMBL26365883 | 0.92 | SLC40A1 (0.39) | SLC40A1EIF2AK3BRAFPLK4EPHB6 | |
| SCHEMBL24257006 | 0.90 | TSHR (0.45) | SLC40A1CYP3A4 | |
| SCHEMBL14734624 | 0.86 | SLC40A1 (0.44) | SLC40A1EIF2AK3BRAFPLK4EPHB6 | |
| SCHEMBL30605882 | 0.86 | SLC40A1 (0.39) | SLC40A1CYP3A4 | |
| SCHEMBL26134904 | 0.86 | SLC40A1 (0.39) | SLC40A1CYP3A4 | |
| SCHEMBL1127359 | 0.85 | CYP3A4 (0.49) | SLC40A1BRAFERN1NR1I2CYP3A4 | |
| SCHEMBL29721239 | 0.85 | CYP3A4 (0.49) | SLC40A1BRAFERN1NR1I2CYP3A4 | |
| SCHEMBL22146305 | 0.85 | SLC40A1 (0.43) | SLC40A1EIF2AK3BRAFPLK4EPHB6 | |
| SCHEMBL2193388 | 0.83 | SLC40A1 (0.38) | SLC40A1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706770-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025132388-A2 | A PROCESS FOR MAKING DABRAFENIB | SYNTHON B.V (NL) | 2025-06-26 | — | — | WO | disclosed |
| US-20240269139-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4397376-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-4159217-B1 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | NOVARTIS AG (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| EP-4232023-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4159217-A1 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2023-04-05 | — | — | EP | disclosed |
| WO-2022093742-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| WO-2011047238-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011047238-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-2282636-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2010104899-A1 | THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | BRAF, RAF1, NRAS | SLC40A1 1035/4885EIF2AK3 3299/4885BRAF 1/4885 |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | SLC40A1 3787/4885EIF2AK3 2901/4885BRAF 776/4885 |
| US-20240269139-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | TTK, MKNK1, MAP3K20 | SLC40A1 4766/4885EIF2AK3 663/4885BRAF 77/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | SLC40A1 3787/4885EIF2AK3 2901/4885BRAF 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.